A Phase 2 interventional study of SOF/VEL and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-02.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 71st largest by enrollment, is one of 11 that started in 2017, is one of 31 in phase 2, and was the 58th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 11 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 84th largest by enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2017, is one of 47 in phase 2, and was the 102nd registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of the treatment with sofosbuvir velpatasvir (SOF/VEL) fixed-dose combination (FDC) with ribavirin (RBV) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection and Child-Pugh-Turcotte (CPT) Class C cirrhosis.
Key Inclusion Criteria:
Individuals may be non-transplanted or with recurrent HCV post-liver transplant.
Key Exclusion Criteria:
Current or prior history of any of the following:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SOF/VEL FDC plus RBV for 12 weeks
Drug: SOF/VEL · Drug: RBV
Drug pages: Sofosbuvir · Velpatasvir
400/100 mg FDC tablet administered orally once daily
Also known as: Epclusa®, GS-7977/GS-5816
Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Study Drug (SOF/VEL or RBV) Due to an Adverse Event
Time frame: First dose date up to Week 12
Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ 4 weeks after stopping study treatment.
Time frame: Posttreatment Week 4
Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24)
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
Time frame: Posttreatment Week 24
Percentage of Participants With HCV RNA < LLOQ While on Study Treatment
Time frame: Weeks 2, 4, 8, and 12
Percentage of Participants With No Change, Improved, and Worsened Child-Pugh-Turcotte (CPT) Class
CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. Participants with no change CPT class was defined as having CPT Class same between Baseline and Posttreatment Week 24.
Time frame: Baseline to Posttreatment Week 24
Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.
Time frame: Baseline to Posttreatment Week 24
Absolute HCV RNA Level Through Week 12
Time frame: Baseline; Weeks 2, 4, 8, and 12
Change From Baseline in HCV RNA
Time frame: Baseline; Weeks 2, 4, 8, and 12
Number of Participants With Virologic Failure
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit
Time frame: Baseline up to Posttreatment Week 24
Participants were enrolled at study sites in the United States and France. The first participant was screened on 23 January 2017. The last study visit occurred on 12 December 2018.
| Milestone | SOF/VEL+ RBV |
|---|---|
| Started | 32 |
| Completed | 23 |
| Not completed | 9 |
| Withdrew: Death | 8 |
| Withdrew: Withdrew consent | 1 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) | 78.1 (60.0 to 90.7) | 72.2 (46.5 to 90.3) | 80.0 (28.4 to 99.5) | 85.7 (42.1 to 99.6) |
| percentage of participants | SOF/VEL+ RBV |
|---|---|
| Discontinuation of SOF/VEL | 6.3 |
| Discontinuation of RBV | 21.9 |
SVR4 was defined as HCV RNA \< LLOQ 4 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Therapy (SVR4) | 87.5 (71.0 to 96.5) | 88.9 (65.3 to 98.6) | 80.0 (28.4 to 99.5) | 85.7 (42.1 to 99.6) |
SVR24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.
| percentage of participants | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Percentage of Participants With Sustained Virologic Response 24 Weeks After Discontinuation of Therapy (SVR24) | 75.0 (56.6 to 88.5) | 72.2 (46.5 to 90.3) | 80.0 (28.4 to 99.5) | 71.4 (29.0 to 96.3) |
| Percentage of participants | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Week 2 | 43.8 (26.4 to 62.3) | 38.9 (17.3 to 64.3) | 0 (0.0 to 52.2) | 71.4 (29.0 to 96.3) |
| Week 4 | 96.6 (82.2 to 99.9) | 100.0 (79.4 to 100.0) | 75.0 (19.4 to 99.4) | 100.0 (59.0 to 100.0) |
| Week 8 | 100.0 (88.1 to 100.0) | 100.0 (79.4 to 100.0) | 100.0 (39.8 to 100.0) | 100.0 (59.0 to 100.0) |
| Week 12 | 100.0 (88.1 to 100.0) | 100.0 (79.4 to 100.0) | 100.0 (39.8 to 100.0) | 100.0 (59.0 to 100.0) |
CPT is a chronic liver disease classification system. Classes include CPT Class A, CPT Class B, and CPT Class C, in order of greater disease severity. Participants with improved CPT class was defined as having Class C at Baseline and Class B or A at Posttreatment Week 24 or Class B at Baseline and Class A at Posttreatment Week 24. Participants with worsened CPT class was defined as having Class A at Baseline and Class B or C at Posttreatment Week 24 or Class B at Baseline and Class C at Posttreatment Week 24. Participants with no change CPT class was defined as having CPT Class same between Baseline and Posttreatment Week 24.
| Percentage of participants | SOF/VEL+ RBV |
|---|---|
| Improved CPT Class | 42.1 |
| Worsened CPT Class | 0 |
| No Change CPT Class | 57.9 |
MELD score is a chronic liver disease severity scoring system. Scores can range from 6 to 40, with higher scores indicating greater disease severity. "No change" was assigned for differences (posttreatment visits minus baseline score) of -1, 0 or 1; "Decrease" was assigned for differences that were less than or equal to -2; and "Increase" was assigned for values that were greater than or equal to 2.
| percentage of participants | SOF/VEL+ RBV |
|---|---|
| Decrease (Improvement) | 52.6 |
| No Change | 21.1 |
| Increase (Worsening) | 26.3 |
| log10 IU/mL | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Baseline | 5.17 ± 1.187 | 5.46 ± 0.537 | 6.01 ± 0.502 | 4.84 ± 1.058 |
| Week 2 | 1.46 ± 0.392 | 1.47 ± 0.387 | 1.63 ± 0.150 | 1.43 ± 0.526 |
| Week 4 | 1.15 ± 0.00 | 1.15 ± 0.000 | 1.15 ± 0.000 | 1.15 ± 0.000 |
| Week 8 | 1.15 ± 0.00 | 1.15 ± 0.000 | 1.15 ± 0.000 | 1.15 ± 0.000 |
| Week 12 | 1.15 ± 0.00 | 1.15 ± 0.000 | 1.15 ± 0.000 | 1.15 ± 0.000 |
| log10 IU/mL | SOF/VEL+ RBV (Total) | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) |
|---|---|---|---|---|
| Change at Week 2 | -3.72 ± 1.092 | -4.06 ± 0.531 | -4.50 ± 0.366 | -3.41 ± 0.665 |
| Change at Week 4 | -3.99 ± 1.238 | -4.39 ± 0.520 | -4.88 ± 0.395 | -3.70 ± 1.058 |
| Change at Week 8 | -4.00 ± 1.217 | -4.39 ± 0.520 | -4.72 ± 0.445 | -3.70 ± 1.058 |
| Change at Week 12 | -4.00 ± 1.217 | -4.39 ± 0.520 | -4.72 ± 0.445 | -3.70 ± 1.058 |
Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit
| Participants | SOF/VEL+ RBV (GT-1) | SOF/VEL+ RBV (GT-2) | SOF/VEL+ RBV (GT-3) | SOF/VEL+ RBV (Total) |
|---|---|---|---|---|
| Number of Participants With Virologic Failure | 0 | 0 | 1 | 1 |
Collected over Adverse Events: First dose date up to Week 12 plus 30 days; All-Cause Mortality: First dose date up to Posttreatment Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF/VEL+ RBV | 8/32 (25%) | 17/32 (53.1%) | 27/32 (84.4%) |
| Event | SOF/VEL+ RBV |
|---|---|
| SepsisInfections and infestations | 2/32 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/32 |
| Hepatic hydrothoraxRespiratory, thoracic and mediastinal disorders | 2/32 |
| Atrial fibrillationCardiac disorders | 1/32 |
| Ventricular tachycardiaCardiac disorders | 1/32 |
| AscitesGastrointestinal disorders | 1/32 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/32 |
| Oedema peripheralGeneral disorders | 1/32 |
| PyrexiaGeneral disorders | 1/32 |
| Dermo-hypodermitisInfections and infestations | 1/32 |
| Event | SOF/VEL+ RBV |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 8/32 |
| NauseaGastrointestinal disorders | 8/32 |
| AstheniaGeneral disorders | 6/32 |
| VomitingGastrointestinal disorders | 5/32 |
| AscitesGastrointestinal disorders | 3/32 |
| ConstipationGastrointestinal disorders | 3/32 |
| DiarrhoeaGastrointestinal disorders | 3/32 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/32 |
| HeadacheNervous system disorders | 3/32 |
| Abdominal painGastrointestinal disorders | 2/32 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | SOF/VEL+ RBV |
|---|---|
| Mean | 55 ± 7.0 |
| Sex: Female, Male(Participants) | SOF/VEL+ RBV |
|---|---|
| Female | 6 |
| Male | 26 |
| Ethnicity (NIH/OMB)(Participants) | SOF/VEL+ RBV |
|---|---|
| Hispanic or Latino | 7 |
| Not Hispanic or Latino | 19 |
| Unknown or Not Reported | 6 |
| Race/Ethnicity, Customized(Participants) | SOF/VEL+ RBV |
|---|---|
| American Indian or Alaska Native | 1 |
| Black or African American Native | 6 |
| White | 18 |
| Not Permitted | 6 |
| Other | 1 |
| Region of Enrollment(participants) | SOF/VEL+ RBV |
|---|---|
| United States | 26 |
| France | 6 |
| HCV RNA(log10 IU/mL) | SOF/VEL+ RBV |
|---|---|
| Mean | 5.2 ± 1.19 |
| HCV RNA Category(Participants) | SOF/VEL+ RBV |
|---|---|
| < 800,000 IU/mL | 23 |
| ≥ 800,000 IU/mL | 9 |
| IL28B(Participants) | SOF/VEL+ RBV |
|---|---|
| CC | 15 |
| CT | 14 |
| TT | 3 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Jan 2017 to primary completion in Sep 2018, 20 months.
Results were first posted in Oct 2019, 1 year after primary completion.
Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 20 months is above that.
Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Velpatasvir · Ribavirin